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A requirement for slc15a4 in
imiquimod-induced systemic
inflammation and psoriasiform
inflammation in mice
Alexis D. Griffith1, Asifa K. Zaidi1, Ashley Pietro1, Matthew Hadiono1, Jessica S. Yang1,
Rachel Davis1 & Daniel L. Popkin1,2
There is competing evidence that plasmacytoid dendritic cells (pDC), the most potent source of IFN-I,
may initiate psoriasis. We targeted pDC function using the slc15a4feeble loss-of-function mouse whose
pDC are unresponsive to TLR agonists. slc15a4feeble treated with the topical TLR7-agonist imiquimod
(IMQ) demonstrated decreased epidermal thickening 24 hours post-treatment which was more
pronounced by day 5 as compared to wildtype mice. These findings were specific to the acute IMQ
model and not the protracted IL23 model that drives inflammation downstream of TLR activation.
Systemically, slc15a4 was required for IMQ-induced weight loss and cutaneous accumulation of CD4+
and Siglec H+, but not CD11b+ cells. Consistent with this phenotype and the function of slc15a4,
induction of IFN-I was virtually absent systemically and via cutaneous gene expression. Induction
of other inflammatory cytokines (cytokine storm) was modestly blunted in slc15a4feeble except for
inflammasome-associated genes consistent with slc15a4 being required for TLR7-mediated (but not
inflammasome-mediated) inflammation downstream of IMQ. Surprisingly, only IFN-I gene expression
was suppressed within IMQ-treated skin. Other genes including conserved psoriasiform trademark
gene expression were augmented in slc15a4feeble versus littermate controls. Taken together, we
have identified a role for slc15a4 but not canonical psoriasiform genes in the imiquimod model of
psoriasiform dermatitis.
Psoriasis is a chronic autoimmune disease affecting approximately 2% of the population1. While the cause of
psoriasis is unknown, there is competing evidence that plasmacytoid dendritic cells (pDC) may be central to
disease development2–5. pDCs are responsible for producing ~1000 times more type I interferon (IFN-I) than any
other cell type. Thus, despite comprising only ~1% of the already rare dendritic cell population, pDCs account
for approximately 50% of all circulating IFN-I following infection6. It has been proposed that pDCs in genetically
predisposed individuals under certain environmental conditions and through their secretion of IFN-I, activate
autoimmune T cells, in turn, eliciting a psoriasiform phenotype4.

Slc15a4.

Solute carrier gene family 15 member 4 (SLC15A4) is a twelve membrane spanning protein also
known as peptide/histidine transporter 1 (PHT1). Slc15a4 cellular gene expression essentially mirrors TLR7 and
9 expression being most highly expressed in antigen presenting cells, specifically plasmacytoid dendritic cells
(pDC) and B cells7–9. Consistently, a functional role for slc15a4 has only been demonstrated in these two cell
types to date. Slc15a4 contains an acidic dileucine motif which likely mediates localization to the endosomal
compartment via AP-37. Subsequent biogenesis of lysosome-related organelles (LROs) harboring TLR7 and TLR9
is defective without slc15a4. Thus TLR7 and TLR9 sensing is specifically lost in slc15a4 mutant mice resulting in
acute loss of IFN-I production secondary to defective pDC within 6 hours post CpG injection7 and loss of B cell
functional responses reported as early as 48 hours after TLR7 and TLR9 stimulation10.
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slc15a4 phenotypes in vivo: SLE, acute and chronic viral infection.

Consistent with the specific
function and expression of slc15a4, slc15a4feeble loss of function mice are protected in the NZB and Fas(lpr) mouse
models of systemic lupus erythematosus (SLE)11. GWAS studies have likewise identified slc15a4 as a genetic locus
contributing to human lupus in 6 independent studies12–17.
The physiological role of slc15a4 is likely for protection against pathogens via TLR7/9 sensing. We tested
this hypothesis and found that slc15a4 was not required for control of acute viremia but was necessary for
virus-specific T cell activation and chronic viral clearance18. Here we extend our analysis of slc15a4 to examine its
role in psoriasiform dermatitis mediated by the canonical TLR7 agonist imiquimod as compared to intradermal
IL23 injection.

Imiquimod (IMQ) model, TLR7, IFN-I and plasmacytoid DC (pDC).

The IMQ model of acute skin
inflammation has become the most widely used mouse model in this category over the past several years19. TLR7
sensing via pDC is thought to drive massive IFN-I expression within 6 hours that contributes to the induction of
multiple inflammatory markers and histologic alterations in the skin seen within 12–24 hours19. However, there
is also a vehicle-specific TLR7-independent effect which activates the inflammasome and contributes in part to
the acanthosis and inflammation present in skin20,21. pDC production of IFN-I is an expected dramatic component of the IMQ model and critical to initiate psoriasis in a xenograft model4. However, deficiency of the IFN-I
receptor was reported to have no effect in two IMQ studies5,20, while two subsequent IMQ studies demonstrated
a significant role for the IFN-I receptor (IFNAR1)22,23. Similarly, pDC which are responsible for ~50% of all acute
IFN-I24 has been implicated in psoriasis4 and the IMQ psoriasiform model. Yet surprisingly, targeting these cells
did not result in any significant changes in the IMQ model5.
Here, we evaluated the role of slc15a4 in imiquimod-induced psoriasiform dermatitis. The mouse mutation
examined in our study (feeble) has a one base-pair mutation in slc15a4 rendering the transporter inactive but feeble mice are otherwise genetically identical to their C57BL/6 J wildtype littermates (WT). Consistently, these mice
are indistinguishable from WT during development, including DC and B cell phenotypic populations. However,
there is a dramatic loss of DC function in response to TLR stimulation, especially regarding IFN-I secretion7,10
as well as a defect in IgG2c class switch recombination during CpG-adjuvanted vaccination10. Using this feeble
model, we found significant decreases in disease initiation and progression in slc15a4feeble as compared to WT
mice both locally and systemically.

Results

The role of pDC and IFN-I in the IMQ psoriasiform dermatitis model is controversial in addition to the source
of IFN-I production4,5,20,22,23. Therefore, we examined an alternative target which may also be inhibited therapeutically to treat TLR-pDC driven immune pathology, slc15a4. Slc15a4 is required for pDC TLR7/9 sensing and
subsequent TLR driven IFN-I production7. We and others found that slc15a4 was important in disease models8,11,18,25. Therefore, we hypothesized that studying slc15a4 deficiency in the IMQ psoriasiform dermatitis model
may clarify the role of the TLR7-pDC-IFN-I pathway of immune pathology. A significant role would also justify
slc15a4 as a specific therapeutic target to alleviate disease.

slc15a4 feeble mice are more resistant to imiquimod induced weight loss than epidermal skin
thickening in an acute psoriasiform dermatitis model, but not resistant to IL23 induced skin
inflammation. We applied IMQ or vehicle control to the shaved backs of WT and slc15a4feeble (slc15a4 defi-

cient mice) for 4 consecutive days and terminated the experiment on day 5 to be consistent with most IMQ studies19. Dramatically, slc15a4feeble mice grossly appeared unaffected by IMQ, i.e. no hunching, withered appearance
or decrease in movement was observed in contrast to their WT littermates. Consistently, IMQ-induced weight
loss was not observed in slc15a4feeble as compared to WT mice (Fig. 1A). Similarly, skin punch biopsies demonstrated attenuated acanthosis in slc15a4feeble compared to WT mice as early as 24 hours post IMQ (Fig. 1B). This
difference in skin thickening was greater by day 5 (Fig. 1B and C). To determine the specificity of slc15a4 in this
psoriasiform model, we executed a more chronic model of psoriasiform dermatitis that activates the downstream
inflammatory cascade by direct intralesional injection of IL23 which promotes Th17 skewing. We found that after
11 days, slc15a4feeble had increased ear skin thickness as compared to their WT littermates (Fig. 2A) and acanthosis
similar to that induced by IMQ in WT mice (Fig. 2B). Thus, we reasoned that a slc15a4 pro-inflammatory role
was necessary in the IMQ model potentially by driving a very proximal event in the inflammatory pathway (i.e.
pDC sensing of IMQ).

slc15a4 is required for IMQ-induced recruitment of CD4+ and SiglecH+ cells.

The IMQ model
of psoriasiform dermatitis is driven by cytokine secreting CD4+ T cells of the lymphoid compartment in addition to CD11b+ myeloid cells26,27. These cell types are critical for the local and systemic effects of IMQ that we
observed (Fig. 1). Thus, we compared the inflammatory infiltrate between treated and control WT and slc15a4feeble
mice on day 5 of IMQ treatment to determine if there was a difference in inflammatory cell infiltration by immunohistochemistry (IHC). We also quantitated the presence of the pDC marker SiglecH given the specific loss of
function of pDC in slc15a4 deficient mice. We observed an absence of CD4+ and SiglecH+ cells accumulating in
the treated skin of slc15a4feeble mice as compared to littermate controls by day 5 (Fig. 3A,B). These data implicated
CD4+ T lymphocytes and pDC as potential cell types driving IMQ-driven weight loss and acanthosis via slc15a4.
In contrast, there was an essentially normal accumulation of CD11b+ cells in slc15a4feeble vs. WT mice. Albeit,
slc15a4feeble had a slightly lower absolute number of resident CD11b+ myeloid cells at baseline (Fig. 3A).

slc15a4 is required for IFN-I induction. pDC secrete ~1000x more IFN-I than any other cell type.
Consistently, pDC are responsible for ~50% of all circulating IFN-I during acute viral infections despite being
extremely rare cells6. Given the absence of SiglecH + pDC accumulating in slc15a4feeble, and the central role of
SCientifiC RePorts | (2018) 8:14451 | DOI:10.1038/s41598-018-32668-9
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Figure 1. slc15a4 is required for imiquimod induced weight loss and epidermal thickening. slc15a4feeble and WT
mice were treated with imiquimod (IMQ) and euthanized after 24 hours or 5 days. (A) Significant IMQ-induced
weight loss was observed in WT mice as compared to slc15a4feeble mice (n = 7, 5, 17, 15). (B) Attenuated
IMQ-induced acanthosis was observed in slc15a4feeble mice at 24 hours and 5 days post daily IMQ treatment
compared to WT mice (n = 7, 5, 6, 6, 17, 5). (C) Representative images of H&E stained mouse dorsal skin from
WT and slc15a4feeble mice demonstrated attenuated acanthosis in slc15a4feeble mice compared to WT mice
on day 5 (n = 7, 5, 17, 15). Images taken at 200 × . Scale is the same in all pictures; scale bar = 100 µm. Data
combined from 3 independent experiments. *p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.0001 in unpaired
two-sided parametric T tests.
pDC in IMQ responses28–30, we hypothesized that slc15a4 would be required for IMQ-induced IFN-I. We found
that the loss of slc15a4 accounted for >1.5 log decrease in IFN-I production (Fig. 4).

slc15a4 contributes to systemic cytokine storm during topical IMQ treatment.

IFN-I treatment
is known to cause weight loss and general malaise that is associated with general inflammation31. Thus, we reasoned that IMQ-induced systemic IFN-I would likely propagate a broad induction of circulating inflammatory
cytokines (“cytokine storm”). We measured 25 cytokines to address this possibility (Fig. 5). We found a potent
induction of almost all 25 cytokines by IMQ. This induction was either unchanged or attenuated in slc15a4feeble.
This attenuation was not generally due to a higher steady state concentration of cytokines in slc15a4feeble as absolute plasma concentrations were overall very similar as compared to WT mice (Supp. Fig. 5). Only CXCL6(24 h
and day 5), IL-1a (24 h only) and IL-6 (24 h only) were increased in slc15a4feeble as compared to WT mice. These
cytokines share a common nidus, inflammasome activation32,33. Induction of IL1b (the canonical output of the
inflammasome) did not meet statistical significance, although it did trend in the same direction (Fig. 5).
SCientifiC RePorts | (2018) 8:14451 | DOI:10.1038/s41598-018-32668-9
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Figure 2. s1c15a4feeble mice exhibit increased inflammation of the ear following intralesional injections of
IL23. Ears of WT and slc15a4feeble mice were injected every other day for 16 consecutive days with 20uL PBS
containing 500 ng IL23. (A) On day 16, ears were collected for staining and measurement via H&E. (B) Ears
were measured every other day with a micrometer, before injections (n = 7, 7, 6). (C) Representative H&E
sections of mouse ears following treatment with IL23 (n = 7, 7, 6, 6). Images taken at 200x. Scale is the same
in all pictures; scale bar = 100 µm. Data from two independent experiments each containing 6–7 mice/group.
*p < 0.05, ***p < 0.0005, ****p < 0.0001 in unpaired two-sided parametric T tests.

Unexpected more potent induction of trademark psoriasiform genes and inflammatory
cytokines in skin of slc15a4 deficient mice. Lastly, we asked whether the IMQ-treated skin may con-

tribute to the systemic increase in circulating cytokines. To address this we isolated total RNA from the treated
skin 24 hours and on day 5 post initiation of treatment and quantitated gene expression for those cytokines identified in the luminex assay above, with validated TaqMan primer-probesets available. We added IL12b and IL23a
given their central role in psoriasiform inflammation as the canonical gene products driving Th1 and Th17 skewing, respectively34. To further evaluate inflammasome associated genes, review of the literature demonstrated
IL1f6 (IL-36a) and CXCL5 as additional IMQ-induced gene products35,36. RT-qPCR demonstrated induction
of many of these cytokines at 24 h in WT mice (Fig. 6A) similar to what we observed in the plasma (Fig. 5A).
However, this local skin induction was largely absent by day 5, consistent with downstream elaboration of circulating cytokines by immune cells which have left the treated skin in WT mice (Fig. 6A). This correlation with
plasma proteins included the relative increase of inflammasome-related genes in in slc15a4feeble compared to
WT mice (Figs 5A and 6A) in addition to a moderate increase in the Th1 and Th17 skewing gene products
IL12b and IL23a, respectively. Surprisingly, we found more potent gene induction of inflammatory cytokines
within the skin of overall less-inflamed slc15a4feeble mice by day 5 (Figs 5B and 6D). This could not be generally
explained by lower basal gene expression in slc15a4feeble mice (Fig. 6S). Taken together, we concluded that local
skin gene induction of inflammatory cytokines may play a role in the first day of IMQ treatment. However, by
day 5 the absence of weight loss and diminished cytokine storm in slc15a4feeble could not be correlated with local
gene expression. Thus, we reasoned that local gene expression could not serve as the predominant source for
SCientifiC RePorts | (2018) 8:14451 | DOI:10.1038/s41598-018-32668-9
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Figure 3. IMQ-dependent recruitment of CD4 + T cells into the dermis requires slc15a4. slc15a4feeble and
WT mice were shaved and treated with imiquimod (IMQ) or only shaved and euthanized after 5 days. (A)
Quantitative measurements of CD4 T-cell (CD4), myeloid cell (CD11b) and pDC (Siglec H) infiltrate from
immunostained dorsal mouse skin of WT and slc15a4feeble mice 5 days post topical treatment with IMQ or
control. n = 4, 5, 4, 5 mice for WT, slc15a4feeble, WT + IMQ, slc15a4feeble + IMQ, respectively. (B) Representative
immunostained sections of dorsal mouse skin at 6 days post treatment with IMQ. n = 4, 5, 4, 5 images from left
to right. Images taken at 200x. Scale is the same in all pictures; scale bar = 100 µm. Data is from 1 of 3 similar
experiments with 4–5 mice/group. *p < 0.05, **p < 0.005, in unpaired two-sided parametric T tests.

circulating cytokines on day 5. We than measured the most strongly increased trademark psoriasisform genes
conserved across humans and 5 mouse models of psoriasiform dermatitis (including IMQ-induced)35 (Fig. 6B,E).
Despite diminished IMQ-induced acanthosis in slc15a4feeble (Fig. 1), we found more potent induction of the 5
most induced genes conserved across animal models and human psoriasis at 24 h and this increase was maintained on day 5 (Fig. 6B,E). We then confirmed that the genes whose regulation were most diminished in magnitude and over time in slc15a4feeble were the type I interferon genes: Ifna2 and Ifnb1 but not type II interferon
(gamma) (Fig. 6C,F). Thus, we concluded that increased induction of psoriasis-associated genes is not sufficient
for maximal skin thickening and that diminished IFN-I, both local and systemic, was the most likely culprit.

Discussion

The role of IFN-I in the IMQ model of psoriasiform dermatitis is controversial5,20,22,23. The most potent producer
of IFN-I is the very rare pDC cell type. Thus efforts to target this cell type systemically for elimination can be difficult to access throughout the animal given the potential critical effects of even a few remaining cells. Additionally,
compensatory responses are possible in the absence of this cell type. Therefore, we chose an alternative approach
to access a potential therapeutic intervention for pDC-TLR7 driven immune pathology, genetic disruption of
slc15a4. Slc15a4 is required for pDC TLR7/9 sensing and subsequent TLR driven IFN-I production7. We and
others previously found that this pathway was important in disease models11,18,37. Therefore, we hypothesized
that studying slc15a4 deficiency in the IMQ-induced psoriasiform dermatitis model may serve as an alternative
SCientifiC RePorts | (2018) 8:14451 | DOI:10.1038/s41598-018-32668-9
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Figure 4. slc15a4 is required for type 1 interferon induction. Plasma was collected 6 and 9 hours post IMQ from
WT and slc15a4feeble mice. IFN-I levels were than measured by ELISA. n = 4/group. 1 of 2 similar experiments
shown. ***p < 0.0005, ****p < 0.0001 in unpaired two-sided parametric T tests.

Figure 5. slc15a4 contributes to IMQ driven cytokine storm. Inflammatory cytokine plasma concentrations
were measured following IMQ treatment using a 25-cytokine luminex assay. Fold changes (IMQ-treated at the
indicated timepoint/time = 0) are shown at 24 hours (A) and 5 days (B). Cytokines were rank-ordered for IMQinduction in WT. The dotted line represents where IMQ treatment does not affect circulating cytokine levels.
The ratio of IMQ-induced fold changes are displayed in blue (decreased), red (increased) and black (<1.5x
changed) comparing mutant to WT. Data was combined from three independent experiments with a total of
5–13 mice per group. *p < 0.05 in unpaired T-test after multiple comparison correction.
strategy to specifically disrupt this pathway. These experiments also demonstrate the potential utility of targeting slc15a4 therapeutically. slc15a4feeble mice, lacking pDC sensing, exhibited attenuated local and systemic IMQ
effects compared to WT mice.
It is also possible that the effect of slc15a4 deficiency is mediated in part via B cells. However, this is less likely
as the reported effects of slc15a4 deficiency in B cells generally occur later than the phenotypes described here in
an acute 5 day IMQ model. The only other cell type reported to be affected directly by slc15a4 deficiency is mast
cells. However, slc15a4−/− mast cells degranulate more potently than their WT counterparts38 which would not
explain our overall observations.
SCientifiC RePorts | (2018) 8:14451 | DOI:10.1038/s41598-018-32668-9
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Figure 6. Unexpected more potent induction of trademark psoriasiform genes and inflammatory cytokines
over time in skin of slc15a4 deficient mice. RT-qPCR analysis of inflammatory genes elevated in 25plex cytokine
analyses in IMQ-treated mice 24 hours (A) and 5 days (D) post treatment with IMQ. IL12b and IL23a were
added to address Th1 and Th17 skewing, respectively. Cytokines were rank ordered from greatest to least
induction in WT. Expression of trademark psoriasiform genes conserved between human and 5 mouse models
is shown rank ordered for human psoriasis at 24 hours (B) and 5 days (E) post-treatment with IMQ. Otherwise,
all other datasets are rank ordered for WT mouse induction. IFN-associated genes are shown 24 hours (C) and
5 days (F) post-treatment with IMQ. Fold change = IMQ relative quantity (RQ)/control RQ, see Materials and
Methods for further details. Data is representative of 3 combined experiments with 5–13 mice/group. n.d. = not
detected. *p < 0.05 in unpaired T-test after multiple comparison correction.

Given the acute effects of IMQ are largely driven via pDC TLR7 sensing28–30, we suspect that pDCs mediate
the majority of the phenotype in slc15a4feeble. However, the opposite phenotype found in the IL23 model could
involve B cells and/or mast cells. These cell types (especially mast cells in the acute setting) may participate in the
apparently paradoxical observation of increased inflammasome-related systemic inflammatory cytokines (Fig. 5)
and the unexpected increase in cutaneous pro-inflammatory gene expression (Fig. 6). Another explanation for
these surprising findings could be inflammatory gene expression compensatory feedback in the absence of IFN-I,
the latter of which is likely necessary for acanthosis as IFN-I protein and gene expression was consistently the
most decreased pathway in slc15a4feeble compared to WT mice.
Although slc15a4 is tightly expressed in DC and B cells, we considered the possibility that slc15a4feeble may
have behavioral differences that contributed to our phenotypes19. However, no difference in grooming behaviors
were observed between slc15a4feeble and WT mice. Additionally, IMQ was applied until it was fully absorbed via
visual inspection to help ensure that any inflammatory differences between WT and mutant mice were not confounded by differential uptake of IMQ or uptake via a different route (i.e. orally).
To understand the basis for the striking absence of weight loss in comparison to the more modest skin changes
in slc15a4feeble, we examined circulating inflammatory cytokines as a possible explanation. We found diminished
induction of 11/25 and 7/25 IMQ-induced circulating cytokines (24 h and day 5, respectively) that supported
this hypothesis (Fig. 5). In addition, the most sustained inflammatory defect in slc15a4feeble was an absence of
IFN-I induction observed at all times at the level of protein and RNA expression when IFN-I is most prominently
induced both systemically and locally (Figs 4 and 6). We suspect that the absence of weight loss in slc15a4feeble
during IMQ treatment is likely due to reduced IFN-I and/or other cytokines in circulation. Strikingly, three
cytokines were upregulated at 24 h and 5 days post IMQ treatment in slc15a4feeble versus WT mice. These were all
inflammasome-related cytokines32,33,39,40. The IMQ psoriasiform model is mediated by the TLR7 vs. inflammasome pathways20. slc15a4 is required for TLR7 sensing via pDC consistent with diminished acanthosis, weight
loss (Fig. 1), immune cell recruitment (Fig. 3), cytokine storm (Figs 4 and 5) and cutaneous induction of several genes at 24 h (Fig. 6). However, some inflammation remained in slc15a4 during IMQ topical treatment as
measured by acanthosis (Fig. 1) with preserved recruitment of myeloid immune cells (Fig. 3). Our data supports the activation of the inflammasome as a potential etiology for this residual acanthosis whose activation is
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independent of slc15a4 consistent with its reported function. Specifically, the relatively heightened concentration
of inflammasome-related cytokines in the plasma (Fig. 5) and inflammasome-related genes in the treated skin
(Fig. 6) support a molecular basis for residual IMQ-induced inflammation without pDC-TLR7 sensing. Residual
markers of molecular inflammation in slc15a4feeble was most striking for the trademark genes whose induction is
conserved across human psoriasis and mouse models35 at 24 h and subsequently, most inflammatory cytokines
surveyed on day 5 (Fig. 6). Taken together, we reason that pDC-TLR7 sensing can be targeted via slc15a4 and is
critical for the inflammatory cascade which results in significant morbidity and weight loss in the IMQ model
of psoriasisform dermatitis. In this IMQ-induced model, loss of slc15a4 is most tightly tied to a defect in IFN-I
production while an inflammasome signature is preserved.

Materials and Methods

Mice. All mice used in this study were housed in the Case Western Reserve University Biomedical Research
Building Animal Facility. C57BL/6 J mice were bred locally or ordered from Jackson Laboratories. slc15a4feeble/feeble
(MGI: 4835997) mutants have been described previously7.
Imiquimod challenge model.

Briefly, slc15a4feeble and C57BL/6 J mice were used at 6–8 wks of age and
gender did not determine different outcomes. Mouse dorsal skin was treated with IMQ, for 1 day or 5 consecutive
days, followed by harvest of tissue and plasma. The dorsal skin of wildtype and feeble mice were shaved prior to
IMQ application. 0.05 g/mouse of IMQ cream (5%), vehicle only, or no cream was applied to the shaved skin of
the mice. Clinical phenotypes (weight loss and acanthosis as described previously19) were identical between vehicle only and no cream conditions.

IL23 challenge model.

Briefly, slc15a4feeble and C57BL/6 J mice were used at 6–8 wks of age and gender
did not affect different outcomes. Mice received intralesional injections of 20 μl PBS, either alone or containing
500 ng recombinant mouse IL-23 (eBioscience), using a 26-gauge needle every other day for 16 days as previously
described41. Ear thickness was measured via micrometer before injection on day 0 and thereafter on days without
injections.

Immunohistochemistry.

Skin was embedded fresh in Tissue Freezing Media (TFM; Triangle Biomedical),
flash frozen in liquid nitrogen and immediately stored at −80 °C. Remaining treated dorsal skin was flash frozen
and stored at −80 °C for use in RNA experiments. Immunohistochemistry was performed on 8 μm sections.
Antibodies and isotype controls were detected using either rabbit anti-rat IgG biotinylated or goat anti-rabbit IgG
biotinylated, amplified with Avidin/Biotinylated Enzyme Complex (ABC, Vector) and were visualized using the
enzyme substrate diaminobenzidine (Vector). Slides were counterstained with hematoxylin and imaged as previously described42. Three different observers have quantified each image manually on two occasions.

RNA Isolation and RT-qPCR.

Dorsal skin was homogenized in TRIzol using a Mikro-Dismembrator
(Sartorius Stedim Biotech, Edgewood, NY) and RNA isolated using RNeasy Mini Kit (Qiagen, Valencia, CA).
Transcriptor First Strand cDNA Synthesis Kit (Roche) was performed following the manufacturer’s instructions.
RT-qPCR was than performed using TaqMan microfluidic array technology from Applied Biosystems on an ABI
7900HT. Relative Quantity (RQ) expression levels were calculated using the comparative CT method (ΔΔCT)
and normalized by GAPDH for: Ifn-gamma, Ifn-beta, Siglec H, Gmcsf, Il-2, Il-7, Il-10, Ccl5, Ccl3, Ccl4, Il-13,
Il-23, S100a7a, S100a9, S100a8, Cxcl1010, IL-1f6, Tnf-a, Il-12p40, Serpinb3c, IL-1 alpha, Has3, Lcn2, Sprr1b,
Pcdh21, Icos, Il-17, Ccl5, Ifna2, and Lor. Absolute values of all measured genes, at baseline and induction, is
described in the Supplementary Figures 1, 2.

Analysis of circulating cytokines. Plasma collected at 24 h and 5 days was interrogated with a 25plex
luminex screening assay (R&D systems) on a Biorad Bioplex Magpix Multiplex Luminex Microplate Reader by
the CWRU Bioanalyte core for IL-12p70, VEGF, IL-1beta, CCL2, CXCL2, IL-6, IL-4, IL-2, TNFalpha, CXCL1,
IL-17, IL-10, IL-13, IL-5, IFNgamma, CXCL10, CCL5, G-CSF, M-CSF, CCL4, IL-1alpha, CCL3, GM-CSF,
CXCL6, and CCL11. IFN-I was measured in plasma by ELISA per manufacturer’s instructions (PBL Assay
Science). Absolute values of all measured circulating cytokines, at baseline and induction, is described in the
Supplementary Figures 3–8.
Statistical Analysis. Unpaired two-sided parametric T-tests were performed between WT and WT + IMQ

groups at each time point in addition to comparing slc15a4feeble and slc15a4feeble + IMQ groups where indicated.
When more than 4 groups were compared, statistical significance was determined using the Holm-Sidak method
to correct for multiple comparisons with alpha = 5%, as indicated. Each row was analyzed individually, without
assuming a consistent SD.

Ethical Approval.

Experimental protocols were approved by Case Western Reserve University Institutional
Animal Care and Use Committee (IACUC) institutional committee under IACUC protocol # 2014-0106.
Specifically, Less than 5 mice were housed per cage with daily monitoring to ensure optimal animal welfare and to
ameliorate suffering. All mouse studies have been conducted according to national and international guidelines
and in accordance with institutional regulations governing animal care and useas detailed in IACUC# 2014-0106.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding
author on reasonable request.
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